Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 4/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | ASAH1 | Q13510 | 2/20 | 0.78 |
| ▸ | TP53 | P04637 | 2/20 | 0.75 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.75 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.75 |
| ▸ | MAPT | P10636 | 1/20 | 0.75 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.75 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.75 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.75 |
| ▸ | ASAH2 | Q9NR71 | 2/20 | 0.71 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.70 |
| ▸ | PLA2G4A | P47712 | 4/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4133213 | 1.00 | CETP (1.00) | CETPTHRBMEN1KMT2AASAH1 | |
| SCHEMBL13863420 | 1.00 | CETP (1.00) | CETPTHRBMEN1KMT2AASAH1 | |
| SCHEMBL22973496 | 1.00 | CETP (1.00) | CETPTHRBMEN1KMT2AASAH1 | |
| SCHEMBL5527047 | 1.00 | CETP (1.00) | CETPTHRBMEN1KMT2AASAH1 | |
| SCHEMBL22911186 | 1.00 | CETP (1.00) | CETPTHRBMEN1KMT2AASAH1 | |
| SCHEMBL22973426 | 1.00 | CETP (1.00) | CETPTHRBMEN1KMT2AASAH1 | |
| SCHEMBL24032894 | 1.00 | CETP (1.00) | CETPTHRBMEN1KMT2AASAH1 | |
| SCHEMBL22973497 | 1.00 | CETP (1.00) | CETPTHRBMEN1KMT2AASAH1 | |
| SCHEMBL22910831 | 1.00 | CETP (1.00) | CETPTHRBMEN1KMT2AASAH1 | |
| SCHEMBL22910800 | 1.00 | CETP (1.00) | CETPTHRBMEN1KMT2AASAH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 692 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4223352-B1 | DRUG-COATED BALLOON CATHETERS FOR BODY LUMENS | UROTRONIC INC (US) | 2026-05-27 | — | — | EP | claimed |
| WO-2026090328-A1 | WNT7a MRNA LIPID NANOPARTICLES FOR THERAPEUTIC USES | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2026-04-30 | — | — | WO | claimed |
| US-12605342-B2 | Polymer-encapsulated drug particles | TONIC MEDICAL, INC. (US) | 2026-04-21 | — | — | US | claimed |
| EP-4658313-A1 | HSC-SPECIFIC ANTIBODY CONJUGATED LIPID NANOPARTICLES AND USES THEREOF | GENZYME CORPORATION (US) | 2025-12-10 | — | — | EP | claimed |
| US-20250336540-A1 | METABOLITE PREDICTORS FOR LUNG CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2025-10-30 | — | — | US | claimed |
| WO-2025151073-A1 | COMPOSITION AND NANOPARTICLE SUITABLE FOR USE IN THE DELIVERY OF A THERAPEUTIC AGENT | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2025-07-17 | — | — | WO | claimed |
| EP-4584278-A1 | 2-AMINOPROPANE-1,3-DIOL-CAPPED CATIONIC PEPTOIDS FOR NUCLEIC ACID DELIVERY | Nutcracker Therapeutics, Inc. (US) | 2025-07-16 | — | — | EP | claimed |
| WO-2025137277-A1 | DEGRADABLE PEPTOIDS | NUTCRACKER THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | claimed |
| WO-2025123045-A1 | PREDICTIVE AND DIAGNOSTIC SCREENING METHODS FOR ENDOMETRIAL CANCER | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2025-06-12 | — | — | WO | claimed |
| EP-4565275-A1 | NUCLEIC ACID COMPOSITIONS COMPRISING AMPHIPHILIC OLIGO ETHYLENE GLYCOL (OEG)-CONJUGATED COMPOUNDS AND METHODS OF USING SUCH COMPOUNDS AND COMPOSITIONS | BioNTech SE (DE) | 2025-06-11 | — | — | EP | claimed |
| EP-3442612-A1 | DRUG-COATED BALLOON CATHETERS FOR BODY LUMENS | Urotronic, Inc. (US) | 2019-02-20 | — | — | EP | claimed |
| US-20190015639-A1 | DRUG-COATED BALLOON CATHETERS FOR BODY LUMENS | JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT | 2019-01-17 | — | — | US | claimed |
| US-20190015640-A1 | DRUG-COATED BALLOON CATHETERS FOR BODY LUMENS | JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT | 2019-01-17 | — | — | US | claimed |
| WO-2018204782-A1 | DRUG-COATED BALLOON CATHETERS FOR BODY LUMENS | UROTRONIC, INC. (US) | 2018-11-08 | — | — | WO | claimed |
| US-20180104383-A1 | DRUG COATED BALLOON CATHETERS FOR NONVASCULAR STRICTURES | JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT | 2018-04-19 | — | — | US | claimed |
| EP-3285820-A1 | DRUG COATED BALLOON CATHETERS FOR NONVASCULAR STRICTURES | Urotronic, Inc. (US) | 2018-02-28 | — | — | EP | claimed |
| WO-2016172343-A1 | DRUG COATED BALLOON CATHETERS FOR NONVASCULAR STRICTURES | UROTRONIC, INC. (US) | 2016-10-27 | — | — | WO | claimed |
| US-6830919-B1 | For ceramide metabolism/formation of fatty acid and sphingoid; genetic engineering; for treatment of metabolic disorders | TAKARA BIO INC. (JP) | 2004-12-14 | — | — | US | claimed |
| US-20040023922-A1 | Lipids for modulating immune response | PORTER WILLIAM LESLIE (GB) | 2004-02-05 | — | — | US | claimed |
| US-6076530-A | APPLYING AMIDE WITH AT LEAST ONE FATTY CHAIN, EXCEPT COPRAH DIETHANOLAMIDE, STEAMING, COOLING; IMPROVED SOFTNESS, SMOOTHNESS | L'OREAL (FR) | 2000-06-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605342-B2 | Polymer-encapsulated drug particles | MUC1, SLC10A2, EGFR | CETP 948/4885THRB 266/4885MEN1 2428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.